Cara Therapeutics
About:
Cara Therapeutics is a biotechnology company focused on developing therapeutics to treat diseases associated with pain and inflammation.
Website: http://www.caratherapeutics.com
Twitter/X: caratherapinc
Top Investors: Connecticut Innovations, Mitsubishi UFJ Capital, Mitsubishi Corporation, HealthCare Royalty Partners, Mitsubishi Motors
Description:
Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patented compound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology.
$517M
$10M to $50M
Shelton, Connecticut, United States
2004-07-02
info(AT)caratherapeutics.com
Derek Chalmers, Frederique Menzaghi, Michael E. Lewis
101-250
2023-11-02
Public
© 2025 bioDAO.ai